Split History
| Home |
| Free Dividend Report |
| Stock Splits Calendar |
| BOLT Stock Split History |
| Preferred Stock Newsletter |
| BOLT Options Chain |
| Stock Message Boards |
Bolt Biotherapeutics (BOLT) has 1 split in our BOLT split history database. The split for BOLT took place on January 31, 2008. This was a 3 for 2 split, meaning for each 2 shares of BOLT owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split.
When a company such as Bolt Biotherapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the BOLT split history from start to finish, an original position size of 1000 shares would have turned into 1500 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bolt Biotherapeutics shares, starting with a $10,000 purchase of BOLT, presented on a split-history-adjusted basis factoring in the complete BOLT split history.
|
Growth of $10,000.00 Without Dividends Reinvested |
||
| Start date: | 02/05/2021 | |
| End date: | 06/07/2023 | |
| Start price/share: | $32.15 | |
| End price/share: | $1.58 | |
| Dividends collected/share: | $0.00 | |
| Total return: | -95.09% | |
| Average Annual Total Return: | -72.54% | |
| Starting investment: | $10,000.00 | |
| Ending investment: | $491.28 | |
| Years: | 2.33 | |
 |
| About Bolt Biotherapeutics |
| Bolt Biotherapeutics is involved in immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Co.'s proprietary Boltbody™ ISAC (immune-stimulating antibody conjugate) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that directly kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. Co.'s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including those with HER2-low tumors. According to our BOLT split history records, Bolt Biotherapeutics has had 1 split. |
| BOLT Split History Table | |
| Date | Ratio |
| 01/31/2008 | 3 for 2 |
| Energy Stock Splits |
| BOLT is categorized under the Energy sector; below are some other companies in the same sector that also have a history of stock splits:
BP Split History
|
Free BOLT Email Alerts:
